Silence Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Silence TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 3.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 31.4% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 19.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -82.2% betragen.

Wichtige Informationen

-3.1%

Wachstumsrate der Gewinne

19.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	31.4%
Zukünftige Eigenkapitalrendite	-82.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 18

Recent updates

Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Oct 04

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 18

Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Jun 17

Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

May 21

Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Feb 07

Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Nov 27

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:SLN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (GBP Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	17	-91	-76	-63	4
12/31/2025	28	-78	-64	-58	6
12/31/2024	21	-63	-51	-44	6
9/30/2024	16	-59	-44	-44	N/A
6/30/2024	18	-40	-29	-29	N/A
3/31/2024	26	-35	-39	-39	N/A
12/31/2023	25	-43	-39	-39	N/A
9/30/2023	28	-43	-41	-41	N/A
6/30/2023	29	-41	-46	-45	N/A
3/31/2023	23	-43	-39	-39	N/A
12/31/2022	18	-40	-46	-45	N/A
9/30/2022	16	-36	-35	-34	N/A
6/30/2022	16	-39	-31	-30	N/A
3/31/2022	15	-39	3	5	N/A
12/31/2021	12	-39	5	7	N/A
9/30/2021	11	-42	3	4	N/A
6/30/2021	10	-42	2	2	N/A
3/31/2021	8	-35	-24	-23	N/A
12/31/2020	5	-33	-11	-11	N/A
9/30/2020	3	-26	0	1	N/A
6/30/2020	1	-22	12	13	N/A
3/31/2020	1	-21	7	7	N/A
12/31/2019	0	-20	2	2	N/A
9/30/2019	0	-19	-8	-8	N/A
6/30/2019	N/A	-18	-18	-18	N/A
3/31/2019	N/A	-18	-18	-18	N/A
12/31/2018	N/A	-18	-17	-17	N/A
9/30/2018	N/A	-12	-15	-15	N/A
6/30/2018	N/A	-5	N/A	-14	N/A
3/31/2018	0	-3	N/A	-12	N/A
12/31/2017	0	-2	N/A	-10	N/A
9/30/2017	0	-5	N/A	-9	N/A
6/30/2017	1	-9	N/A	-9	N/A
3/31/2017	1	-9	N/A	-9	N/A
12/31/2016	1	-8	N/A	-10	N/A
9/30/2016	0	-8	N/A	-10	N/A
6/30/2016	N/A	-7	N/A	-9	N/A
3/31/2016	N/A	-7	N/A	-9	N/A
12/31/2015	N/A	-7	N/A	-8	N/A
9/30/2015	0	-8	N/A	-9	N/A
6/30/2015	0	-10	N/A	-9	N/A
3/31/2015	0	-10	N/A	-9	N/A
12/31/2014	0	-11	N/A	-9	N/A
9/30/2014	0	-11	N/A	-9	N/A
6/30/2014	0	-11	N/A	-9	N/A
3/31/2014	0	-10	N/A	-8	N/A
12/31/2013	0	-9	N/A	-7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SLN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SLN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SLN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SLNDie Einnahmen des Unternehmens (31.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: SLNDie Einnahmen des Unternehmens (31.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SLN wird voraussichtlich in 3 Jahren unrentabel sein.

Silence Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 15%

Price target increased by 16% to US$49.40

Recent updates

Silence Therapeutics plc Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics plc Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(A)

Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 11%

Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024

Silence Therapeutics plc, Annual General Meeting, May 17, 2024

Silence Therapeutics plc Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

Silence Therapeutics plc Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(A)

Silence Therapeutics plc to Report Q4, 2023 Results on Mar 13, 2024

Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Price target increased by 16% to US$49.40

Silence Therapeutics plc Announces Executive Changes

Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Silence Therapeutics plc Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Silence Therapeutics plc Announces Retirement of Giles Campion as Chief Medical Officer, Head of Research & Development and Member of Board

New major risk - Share price stability

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Provides SLN360 and SLN124 Clinical Program Updates

Silence Therapeutics plc Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Silence Therapeutics plc Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera

Silence Therapeutics wins FDA’s fast track status for blood cancer therapy

Silence Therapeutics prices 5.95M ADSs at $9.50/share

Silence Therapeutics plc, Annual General Meeting, Jun 14, 2022

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

Silence Therapeutics plc to Report Q4, 2021 Results on Mar 17, 2022

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

Silence Therapeutics plc Presents Additional Positive Data from the SLN124 Healthy Volunteer Study

Silence Therapeutics Updates on AIM Delisting

Silence Therapeutics plc announced that it has received $40 million in funding from AstraZeneca PLC

Silence Therapeutics plc Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers

Silence Therapeutics plc to Report Fiscal Year 2020 Results on Mar 30, 2021

Silence Therapeutics plc & Mallinckrodt plc Initiate Work on 3Rd Target

Silence Therapeutics plc announced that it has received $45.499905 million in funding from a group of investors

Silence Therapeutics plc Initiates Dosing in Phase 1 Clinical Trial of Sln360 for Cardiovascular Disease Due to High Lipoprotein(A)

Silence Therapeutics Appoints Michael H. Davidson to Board of Directors

Silence Therapeutics Appoints Craig Tooman as CFO

New finance chief for Silence Therapeutics

Silence Therapeutics plc Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) At American Heart Association 2020

Silence Therapeutics plc Appoints Marie Wikström Lindholm as Senior Vice President, Molecular Design and Member of the Silence Executive Leadership Team

Silence Therapeutics plc Announces Rob Quinn, the Current CFO Will Leave the Company in January 2021

Silence Therapeutics plc announced that it has received $20 million in funding from AstraZeneca PLC

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken